Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
6.23
-0.12 (-1.89%)
Aug 13, 2025, 12:13 PM - Market open
Despegar.com Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
332.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | 125.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CADL News
- 14 days ago - Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 20 days ago - Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 5 weeks ago - Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution - GlobeNewsWire
- 7 weeks ago - Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewsWire
- 2 months ago - Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer - GlobeNewsWire
- 2 months ago - Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation - GlobeNewsWire